Download full-text PDF |
Source |
---|
R I Med J (2013)
February 2025
Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital.
Cardiac Positron Emission Tomography (PET) is a power- ful imaging tool with diverse applications in the detection and diagnosis of various cardiac conditions, including inflammatory, infectious, and neoplastic processes. Using the radiotracer 18F-fluorodeoxyglucose (18F-FDG), cardiac PET enables the identification of cardiac involvement in diseases such as sarcoidosis and severe infections affecting the heart tissue. Additionally, 18F-FDG PET is valuable in the evaluation of cardiac masses, helping to assess their metabolic activity and potential malignancy.
View Article and Find Full Text PDFR I Med J (2013)
February 2025
Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital.
Cardiac Positron Emission Tomography (PET) can be used for the assessment of myocardial perfusion. Compared to other cardiac imaging techniques, notably Single Photon Emission Computer Tomography (SPECT), cardiac PET offers superior image resolution, higher accuracy, quantitative measures of myocardial perfusion, lower radiation exposure, and shorter image acquisition time. However, PET tends to be costlier and less widely available than SPECT due to the specialized equipment needed for generating the necessary radiotracers.
View Article and Find Full Text PDFBiomolecules
January 2025
Department of Radiology, Nemours Children's Health, Delaware, Wilmington, DE 19803, USA.
Tryptophan (Trp)-based radiotracers have excellent potential for imaging many different types of brain pathology because of their involvement with both the serotonergic and kynurenine (KYN) pathways. However, radiotracers specific to the kynurenine metabolism pathway are limited. In addition, historically Trp-based radiopharmaceuticals were synthesized with the short-lived isotope carbon-11.
View Article and Find Full Text PDFBiomolecules
December 2024
Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy.
Prostate cancer (PCa) is a high-prevalence disease usually characterized by metastatic spread to the pelvic lymph nodes and bones and the development of visceral metastases only in the late stages of disease. Positron Emission Tomography (PET) plays a key role in the detection of PCa metastases. Several PET radiotracers are used in PCa patients according to the stage and pathological features of the disease, in particular Ga/F-prostate-specific membrane antigen (PSMA) ligands.
View Article and Find Full Text PDFBMC Med
January 2025
Department of Oncology, University of Oxford, Oxford, UK.
Background: The clinical translation of positron emission tomography (PET) radiotracers for cancer management presents complex challenges. We have developed consensus-based recommendations for preclinical and clinical assessment of novel and established radiotracers, applied to image different cancer types, to improve the standardisation of translational methodologies and accelerate clinical implementation.
Methods: A consensus process was developed using the RAND/UCLA Appropriateness Method (RAM) to gather insights from a multidisciplinary panel of 38 key stakeholders on the appropriateness of preclinical and clinical methodologies and stakeholder engagement for PET radiotracer translation.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!